Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Adenocarcinoma of the Esophagogastric Junction 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Completed × Endoscopy, Digestive System × Clear all
NCT02287129 2023-11-28

MEMORI

Technical University of Munich

Phase 2 Completed
75 enrolled
Gastrointestinal

Adenocarcinoma of the Esophagogastric Junction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡